13.00

7.08% -0.99

Maplight Therapeutics Inc (MPLT)

Overview News Price History Discussions Forecast

Maplight Therapeutics Inc stock is traded at $13.00, with a volume of 276.10K. It is down -7.08% in the last 24 hours and up +0.00% over the past month. MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Previous Close:

$13.99

Open:

$13.8

24h Volume:

276.10K

Relative Volume:

3.93

Market Cap:

$538.58M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-5.04%

1M Performance:

+0.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$12.92

$14.32

1-Week Range:

$12.92

$15.38

52-Week Range:

$12.92

$18.84

Maplight Therapeutics Inc Stock (MPLT) Company Profile

Name

Maplight Therapeutics Inc

Sector

Healthcare (1137)

Industry

Biotechnology (635)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MPLT's Discussions on Twitter

Compare MPLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MPLT Maplight Therapeutics Inc	13.00	610.54M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	424.00	108.28B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	761.45	79.44B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.23	57.65B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	906.74	56.58B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	206.93	42.39B	447.02M	-1.18B	-906.14M	-6.1812

Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-21-25	Initiated	Jefferies	Buy
Nov-21-25	Initiated	Leerink Partners	Outperform
Nov-21-25	Initiated	Morgan Stanley	Overweight
Nov-21-25	Initiated	Stifel	Buy

Maplight Therapeutics Inc Stock (MPLT) Latest News

Nov 24, 2025

MapLight Therapeutics stock rating reiterated at Overweight by Morgan Stanley - Investing.com Canada

Nov 24, 2025

Nov 23, 2025

MapLight Therapeutics initiated with a Buy at Stifel - MSN

Nov 23, 2025

Nov 21, 2025

Jefferies & Co Initiates Coverage on MapLight Therapeutics With Buy Rating, $32 Price Target - MarketScreener

Nov 21, 2025

Morgan Stanley Initiates MapLight Therapeutics at Overweight With $34 Price Target - MarketScreener

Nov 21, 2025

MPLT Analyst Forecasts - Quiver Quantitative

Nov 21, 2025

MapLight Therapeutics stock initiated with Outperform rating by Leerink Partners - Investing.com Canada

Nov 21, 2025

Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential - TipRanks

Nov 21, 2025

Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials - TipRanks

Nov 21, 2025

MapLight Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | MPLT | US56565P1030 - MarketScreener

Nov 21, 2025

MapLight Therapeutics stock initiated with Buy rating at Jefferies By Investing.com - Investing.com Canada

Nov 21, 2025

MapLight Therapeutics stock initiated with Buy rating by Stifel - Investing.com Canada

Nov 21, 2025

Morgan Stanley initiates MapLight Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada

Nov 21, 2025

Nov 19, 2025